Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

It definitely could have more upside potential.

Is This Underappreciated Cathie Wood Stock a Better Buy Than Tesla Right Now?

Fulgent Genetics

These two genetic testing companies have different approaches.

How Do Fulgent Genetics and Invitae Stack Up Against Each Other?

The company unveiled its inaugural ESG report. But the overall rise in growth stocks was its main catalyst.

Why Invitae Stock Jumped Today

SAN FRANCISCO, March 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the issuance of its inaugural Environmental, Social and Governance (ESG) report, augmenting the company's disclosures regarding its ESG strategy and capabilities. "Those of us who have dedicated our careers to improving healthcare understand deeply the impacts of climate change and the environment, social inequity and the actions of corporations on the health of individuals.

Invitae Releases Inaugural Environmental, Social and Governance (ESG) Report

A Relative Strength Rating upgrade for Invitae shows improving technical performance. Will it continue?

Invitae Shows Rising Relative Strength; Still Shy Of Key Benchmark

Cathie Wood's recent comments on CNBC's 'Closing Bell' concerning Invitae (NVTA) stock have shares soaring higher on Tuesday. The post NVTA Stock: The Cathie Wood Comments That Have Invitae Shares Surging Today appeared first on InvestorPlace.

NVTA Stock: The Cathie Wood Comments That Have Invitae Shares Surging Today

Top-line growth should help the company grow its bottom line eventually.

Does Invitae Have a Path to Profitability?

The overall market sell-off dragged Invitae's shares down.

Why Invitae Stock Tumbled Again Today

SAN FRANCISCO, March 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021 at 10:40 a.m. Eastern / 7:40...

Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference

The past 12 months have been a wild ride for the genetic testing company's stock, with a sub-$10 low and a high of more than $60.

Should You Buy Invitae Stock?

The medical genetics company was pulled down by a broader sell-off of growth stocks.

Why Invitae Stock Fell Today

SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its robust clinical workflow and patient education tools. The additional capabilities...

Invitae adds Medneon's risk assessment tools to its education and clinical support offerings

The healthcare company is diving along with the market.

Why Invitae Stock Is Falling Today

Invitae is a genetic testing company that aims to deliver packages of medical information to consumers—by the billions. It enjoys reasonable financial strength but has been consistently unprofitable. In addition, it keeps going back to investors for more capital, diluting the value of previously purchased shares.

Invitae Outlook Remains Positive Even After Continuing Losses, Dilution

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinical chatbot Gia to guide their patients in an intuitive, enjoyable and...

Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians

Why Invitae Stock Fell 11.1% Today

Micron Technology

Seagate Technology Holdings PLC

With the trading day more than halfway over, the broad markets were trading lower with the Dow down about 0.4 while the S&P 500 traded down about 0.5% and Nasdaq traded down nearly 0.9%.

Seagate, Micron, Invitae and More Thursday Afternoon Analyst Calls

Veru

Community Health Systems

Molecular Templates

Community Health Systems (NYSE: CYH) shares are trading higher after the company reported better-than-expected fourth-quarter sales results. Community Health Systems is the largest publicly owned hospital operator in the United States.

Why Veru, Invitae And More Are Moving Today

The company's revenue soared, but so did its expenses.

Why Invitae's Q4 Results Didn't Fire Up Investors

Invitae Corporation (NVTA) CEO Sean George on Q4 2020 Results - Earnings Call Transcript

Shares of Invitae (NYSE:NVTA) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were unchanged 0.00% over the past year to ($0.63), which missed the estimate of ($0.55).

Recap: Invitae Q4 Earnings

Invitae (NYSE:NVTA) unveils its next round of earnings this Wednesday, February 17. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Earnings Preview: Invitae

Invitae's (NVTA) fourth-quarter results are likely to reflect strength in genetic testing.

Invitae (NVTA) to Report Q4 Earnings: What's in the Offing?

Progyny

Vertex Pharmaceuticals

Two innovative small companies with scorching growth and one bargain biotech.

3 Healthcare Stocks I'd Buy Right Now

Invitae (NVTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Invitae Stock (NVTA)